BioSpace News Archive

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced presentations from the Company’s global clinical development programs in hematologic malignancies and solid tumors at the 2022 Annual Meeting of the American Society of Cancer Oncology.

Jaguar Health, Inc. announced that Canalevia-CA1, the company’s prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs, is now available from multiple leading veterinary distributors in the U.S. Canalevia-CA1 received conditional approval from the FDA on December 21, 2021.

Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), today announced that it will present a poster featuring data on AL101 in adenoid cystic carcinoma (ACC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that initial clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 study evaluating PC14586 have been selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

The Feinstein Institutes for Medical Research has selected two scientists from the University of Pennsylvania Perelman School of Medicine, Katalin Karikó, PhD, and Drew Weissman, MD, PhD, as awardees of the ninth annual Ross Prize in Molecular Medicine for their tireless research in messenger RNA technology and contributions to developing mRNA-based vaccines to prevent the coronavirus disease 2019.

The global central nervous system therapeutics market is expected to reach valuation US$ 209.2Bn by 2030 and is estimated to expand at a CAGR of 6.3% from 2021 to 2030

According to Report, the global complementary and alternative medicine market is anticipated to garner notable gains, registering a CAGR of18% during the forecast period 2021-2030.

The global diagnostic imaging services market size is expected to be worth around US$ 818.91 billion by 2029 from US$ 553.66 billion in 2021, growing at a CAGR of 5% during forecast period 2021 to 2030.

The global Active Pharmaceutical Ingredients CDMO market size is expected to surpass around US$ 236.1 billion by 2030 from valued at US$ 91.6 billion in 2020 with a registered CAGR of 12.7% from 2021 to 2030.

The drug discovery services market was valued at approximately USD 12.68 billion in 2021, and it is expected to witness revenue of USD 29.85 billion in 2029, with a CAGR of 11.3% from 2021 to 2030.